Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.
News
-
October 20, 2021Targovax ASA appoints Dr. Erik Digman Wiklund as new CEO
-
October 19, 2021Targovax to present at upcoming conferences
-
October 6, 2021Targovax ASA: Two abstracts accepted at the SITC Congress
-
October 3, 2021Targovax ASA issues options to new member of management
Q2 Second quarter 2021
Targovax ASA announced its second quarter 2021 results on Wednesday August 18, 2021.